The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor.

Congratulations to our client Convoy on its $260 million funding round which will accelerate the development of its efficiency-focused technologies.

Orrick advised VNV Global and Kinnevik in their investments in Babylon's $4.2 billion de-SPAC transaction.

Orrick has advised Turn/River Capital on its investment in Invicti Security’s $625 million funding round, led by Summit Partners.

Orrick advised Apex Clean Energy in the sale of a majority stake in the company to funds and other accounts managed by Ares Management.

Congratulations to our client Sizewise Rentals on its definitive agreement to be acquired by Agiliti for $230 million.